Cialis 10mg

Clinical Monograph: Cialis 10 mg (Tadalafil)

1. Classification and Chemical Overview

Tadalafil is a selective phosphodiesterase type 5 (PDE5) inhibitor belonging to the dipyrazinopyrazine chemical class. Chemically designated as pyrazino[1′,2′:1,6]pyrido[3,4-b]indole-1,4-dione, 6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-, (6R,12aR)-. Under the Anatomical Therapeutic Chemical (ATC) system, tadalafil is indexed under G04BE08.

• Product Context: Cialis is a globally recognized brand-name formulation originally developed by Eli Lilly. The 10 mg strength represents an intermediate standard dose utilized for on-demand use when lower starting doses require adjustment or when a balance between efficacy and tolerability is desired.

• Controlled Status: Regulated as a Prescription Only Medicine (POM). It is not classified as a controlled substance, as it lacks reinforcing central nervous system properties, dependence liability, or abuse potential.

2. Mechanism of Action and Pharmacodynamics

Tadalafil facilitates erectile function by enhancing the physiological nitric oxide signaling cascade during sexual stimulation:

• Nitric Oxide / cGMP Pathway: Sexual stimulation triggers the local release of nitric oxide (NO) in the corpus cavernosum. Nitric oxide activates guanylyl cyclase, increasing intracellular cyclic guanosine monophosphate (cGMP) concentrations, which relaxes smooth muscle and allows blood inflow to produce an erection.

• PDE5 Inhibition: Tadalafil competitively inhibits phosphodiesterase type 5 (PDE5), the enzyme responsible for degrading cGMP in the corpus cavernosum.

• Extended Pharmacodynamic Profile: Tadalafil exhibits high selectivity for PDE5 over other phosphodiesterase enzymes. Its unique structural properties yield an exceptionally long elimination half-life, enabling a duration of therapeutic efficacy that persists for up to 36 hours post-dose.

3. Approved Clinical Indications and Dosing Scope

Licensing for Cialis 10 mg includes:

• Erectile Dysfunction (ED): Treatment of erectile dysfunction, defined as the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.

Dosing & Administration Regimen:

• On-Demand Dosing: Typically administered orally prior to anticipated sexual activity. Unlike shorter-acting PDE5 inhibitors, tadalafil remains effective for up to 36 hours, granting greater temporal flexibility.

• Strength Scope & Titration: The recommended starting dose for on-demand use is generally 10 mg, taken prior to sexual activity. The dose may be increased to 20 mg or decreased to 5 mg based on individual efficacy and tolerability. (Note: Daily low-dose regimens typically utilize 2.5 mg or 5 mg tablets).

• Frequency Restrictions: Do not exceed one dose per 24-hour period for on-demand regimens.

• Administration Precautions: Can be taken with or without food, as food does not significantly affect the rate or extent of absorption.

4. Pharmacokinetic Profile and Metabolic Fate

• Absorption: Readily absorbed following oral administration, with mean maximum plasma concentrations (Cmax​) achieved at a median time of 2 hours post-dose. Oral bioavailability is not influenced by food intake.

• Distribution: Distributes extensively into body tissues, with an average apparent volume of distribution of approximately 63 liters. Plasma protein binding is high (~94%).

• Biotransformation: Extensively metabolized in the liver primarily via the Cytochrome P450 enzyme system, specifically CYP3A4, into inactive metabolites (predominantly methylcatechol glucuronide).

• Elimination: Excreted predominantly as metabolites via the feces (~61%) and to a lesser extent in the urine (~36%). Tadalafil is characterized by a prolonged terminal elimination half-life of approximately 17.5 hours in healthy subjects, explaining its extended duration of action.

5. Physiological Effects and Adverse Event Spectrum

Tadalafil induces systemic vasodilation, smooth muscle relaxation, and mild autonomic modulation.

Adverse Drug Reaction Spectrum

• Very Common ($\ge 1/10$): Headache, dyspepsia.

• Common ($\ge 1/100$ to $<1/10$): Back pain, myalgia, nasopharyngitis, pain in extremity, flushing, nasal congestion, dizziness.

• Uncommon ($\ge 1/1,000$ to $<1/100$): Visual disturbances (including blurred vision, cyanopsia, eye pain), dyspnea, hypotension, hypertension, palpitations, tachycardia, abdominal pain, gastroesophageal reflux, rash, hyperhidrosis.

• Rare / Severe (<1/1,000): Sudden vision loss (non-arteritic anterior ischemic optic neuropathy – NAION), sudden hearing loss or deafness, severe cardiovascular events (myocardial infarction, sudden cardiac death, unstable angina), priapism (prolonged erections exceeding 4 hours), and severe hypersensitivity reactions (including angioedema and urticaria).

6. Contraindications, Drug Interactions, and Clinical Precautions

Controindicazioni

• Known hypersensitivity to tadalafil or formulation excipients.

• Concomitant Nitrates or Nitric Oxide Donors: Absolute contraindication. Co-administration with organic nitrates (e.g., nitroglycerin, isosorbide dinitrate, amyl nitrite “poppers”) can trigger profound, life-threatening systemic hypotension.

• Concomitant Guanylate Cyclase Stimulators: Co-administration with riociguat is strictly contraindicated due to synergistic hypotensive effects.

• Severe Cardiovascular Disease: Patients with myocardial infarction within the last 90 days, unstable angina, severe heart failure, or uncontrolled arrhythmias/hypertension.

• Severe hepatic impairment or end-stage renal disease.

Key Drug Interactions

• Alpha-Blockers (e.g., Doxazosin, Tamsulosin): Co-administration can provoke symptomatic postural hypotension and dizziness due to additive vasodilatory effects; caution and stability on alpha-blocker therapy are required.

• Potent CYP3A4 Inhibitors (e.g., Ketoconazole, Ritonavir, Clarithromycin): Inhibit tadalafil clearance, significantly increasing systemic exposure and adverse event risks.

• CYP3A4 Inducers (e.g., Rifampicin, Carbamazepine, St. John’s Wort): Accelerate tadalafil metabolism, substantially reducing plasma concentrations and therapeutic efficacy.

Clinical Precautions and Monitoring

• Cardiovascular Status Evaluation: Assess cardiovascular risk prior to initiating ED treatment, as sexual activity carries an inherent cardiac burden.

• Prolonged Action & Adverse Management: Advise patients that tadalafil’s extended half-life (up to 36 hours) means adverse effects like myalgia or headache may persist longer than with other PDE5 inhibitors. Instruct patients to seek emergency care for prolonged erections exceeding 4 hours to prevent permanent tissue damage.